Company Filing History:
Years Active: 2019-2022
Title: Michael Mathieson: Innovator in Wnt Signalling Pathway Inhibitors
Introduction
Michael Mathieson is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target the Wnt signalling pathway. With a total of three patents to his name, Mathieson is recognized for his innovative approach to cancer treatment.
Latest Patents
Among his latest patents, Mathieson has developed N-pyridinyl acetamide derivatives as Wnt signalling pathway inhibitors. These compounds are designed to inhibit Porcupine (Porcn), a key player in the Wnt signalling pathway. The invention outlines processes for preparing these compounds and their potential uses in treating various conditions mediated by the Wnt signalling pathway. This includes applications in treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia. Additionally, these compounds may enhance the effectiveness of existing anti-cancer treatments.
Career Highlights
Michael Mathieson is currently associated with Redx Pharma Limited, where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against cancer, showcasing his commitment to improving patient outcomes through innovative therapies.
Collaborations
Mathieson collaborates with talented professionals in his field, including Inder Bhamra and Craig Donoghue. Their combined expertise contributes to the success of their projects and the advancement of cancer treatment options.
Conclusion
Michael Mathieson stands out as an influential inventor in the realm of pharmaceutical innovations. His work on Wnt signalling pathway inhibitors has the potential to make a significant impact on cancer treatment.